

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED

阿里健康信息技術有限公司

(Incorporated in Bermuda with limited liability)

(Stock code: 00241)

PROFIT WARNING

This announcement is made by Alibaba Health Information Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on its preliminary assessment of the unaudited consolidated management accounts of the Group and information currently available to the Board, the Group expects to record a net loss of not more than RMB320 million for the six months ended September 30, 2021 (“**6M FY2021**”) as compared with the net profit of approximately RMB279 million for the corresponding period in 2020. The Group’s net loss for 6M FY2021 was mainly attributable to the following reasons: (i) the increase in the deployment of the Group’s resources to invest in a series of innovative business areas such as the “Dr. Deer” APP and health insurance; (ii) the Group’s continuous investment in drug supply chain capabilities, including drug storage and logistics, as well as operational service improvements in the Group’s pharmaceutical direct sales business, customer experiences in prescription refills and the research and development of the skills for prescription drug regulatory compliance and safety; (iii) the Group’s increasing investment in building the brand awareness of Tmall’s Pharmaceutical Platform and Alibaba Health Pharmacy; (iv) decrease in operating margin of the Group’s direct sales business as the Group increased its market share of online B2C drug sales, accelerated

business deployment of prescription drug sales business and increased the deployment of corresponding market resources; partially offset by (v) the increase in unrealised gain on changes in fair values of investment.

The information contained in this announcement represents a preliminary assessment by the Board with reference to the unaudited consolidated management accounts of the Group and other information available to the Board. Such information has not been reviewed by the auditors or the audit committee of the Company. As the Company is still in the process of finalising its interim financial results for 6M FY2021 (the “**Interim Results**”), the actual results for 6M FY2021 may be different from the information set out in this announcement. Further details of the Interim Results will be included in the Company’s Interim Results announcement, which is expected to be published in late November 2021.

Shareholders and potential investors should exercise caution when they deal or contemplate dealing in the shares or other securities of the Company.

By Order of the Board
Alibaba Health Information Technology Limited
Zhu Shunyan
Chairman and Chief Executive Officer

Hong Kong, October 25, 2021

As at the date of this announcement, the Board comprises seven Directors, of whom (i) three are executive Directors, namely Mr. ZHU Shunyan, Mr. SHEN Difan and Mr. TU Yanwu; (ii) one is a non-executive Director, namely Mr. LI Faguang; and (iii) three are independent non-executive Directors, namely Mr. LUO Tong, Mr. WONG King On, Samuel and Ms. HUANG Yi Fei (Vanessa).